Evidence map›Paper›PMID 35279201›Full record

Trial reportStem cell research & therapy2022

Mid-term prognosis of the stromal vascular fraction for knee osteoarthritis: a minimum 5-year follow-up study.

Shengyang Zhang, Huihui Xu, Bangjian He, Mengqiang Fan, Miaomiao Xiao, Jingjing Zhang, Di Chen, Peijian Tong, Qiang Mao

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 6 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 6 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Stem cell injections for osteoarthritis of the knee.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Comparative outcome analyses of stromal vascular fractionWorld journal of experimental medicine · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Mesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review.International journal of molecular sciences · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shengyang Zhang *Department of Orthopedics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Huihui Xu *The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Bangjian He *Department of Orthopedics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Mengqiang FanThe First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Miaomiao XiaoThe First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Jingjing ZhangThe First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Di ChenShenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen University of Technology, Shenzhen, China.
Peijian TongDepartment of Orthopedics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. tongpeijian@163.com.
Qiang MaoDepartment of Orthopedics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. zyydxmq@126.com.
Zhejiang Chinese Medical University · CNShaoxing People's Hospital · CNShenzhen Institutes of Advanced Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe short-term safety and efficacy of stromal vascular fraction (SVF) in treating knee osteoarthritis (KOA) have been extensively studied but the mid-term and long-term prognoses remain unknown.

methods126 KOA patients were recruited and randomly assigned to SVF group and hyaluronic acid (HA) group (control group). The scores of visual analogue scale (VAS) and the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) were assessed and compared between the two groups 1, 2, 3, and 5 years after treatment. The endpoint was defined as surgeries related to KOA or clinical scores exceeding the patient acceptable symptom state (PASS).

resultsThe VAS and WOMAC scores in the SVF group were significantly better than those in the HA group during the 5-year follow-up after treatment. The average responsive time to SVF treatment (61.52 months) was significantly longer than HA treatment (30.37 months). The adjusted Cox proportional hazards model showed that bone marrow lesion (BML) severity, body mass index (BMI) and treatment were independent risk factors and that the use of SVF reduced the risk of clinical failure by 2.602 times. The cartilage volume was reduced in both the SVF and control groups at 5 years but reduced less in the SVF group.

conclusionsUp to 5 years after SVF treatment, acceptable clinical state was present for approximately 60% of patients. BML severity and BMI were independent predictors of the prognosis. TRIAL REGISTRY: This study was retrospectively registered at Chinses Clinical Trial Registry with identifier ChiCTR2100052818 and was approved by ethics committee of the First Affiliated Hospital of Zhejiang Chinese Medical University, number 2013-X-063.

Indexed as

Osteoarthritis, KneeFollow-Up StudiesHumansHyaluronic AcidInjections, Intra-ArticularStromal Vascular FractionTreatment OutcomeHyaluronic AcidBone marrow lesionFull-thickness cartilage defectKnee osteoarthritisMid-term follow-upPrognosisStromal vascular fraction

Identifiers

PMID35279201
PMCPMC8917679
OpenAlexW4220666391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.